FATE THERAPEUTICS INC (FATE)
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Allient Inc. Elects Alex Collichio as Vice President
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
Duos Technologies Group Sets First Quarter 2026 Earnings Call for Monday, May 18, 2026 at 8:30 AM ET
Axe Compute to Host Q1 2026 Financial Results Conference Call
SoundThinking Honors Law Enforcement During National Police Week 2026
ARRAY Technologies to Participate in Upcoming Investor Conferences
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Amex Exploration annonce un placement privé sursouscrit de 43,5 millions $ CA et un placement privé concomitant additionnel jusqu’à concurrence de 31 millions $ CA
Amex Exploration Announces Oversubscribed C$43.5 Million LIFE Offering and Additional Concurrent Private Placement of Up to C$31 Million